Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?

Table 1 Study summary

Item	Parameter value
Efficacy - clinical outcomes. At the end of the study, 77.45% of the patients were alive, %
CR	9.80
PR	51.19
SD	19.60
PD	18.62
Objective response rate	61.76
Disease control rate	81.37
Median progression-free survival	10.07 months
Median overall survival	26.43 months
Positive factors related to overall survival
BCLC stage	B
LDH	≤ 198.52 U/L
Early NLR response	Decrease
Early AFP response	> 20 ng/mL
Positive factors related to progression-free survival
BCLC stage	B
Early NLR response	Decrease
Early AFP response	> 20 ng/mL

Patients with low tumor burden either at baseline or in response to treatment effects had a better prognosis. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Disease progression; BCLC: Barcelona Clinic Liver Cancer staging; LDH: Lactate dehydrogenase; NLR: Neutrophil-lymphocyte ratio; AFP: Alpha-fetoprotein.